Importance of changes to treatment plans based on pediatric renal transplant biopsy findings in Ireland: a 10-year review

Rachel Tillman1, Danial Jefferelli2, Retaj Mohammad2, Malcolm Lewis, MD3, Maria Stack, MD3, Tara Raftery, PhD3, Michael Riordan, MD3, Atif Awan, MD3

1Medical College of Wisconsin, 2University College Dublin, 3Temple Street Children’s University Hospital

Introduction

- The therapeutic value of protocol biopsies in pediatric renal transplantation remains unclear worldwide
- The use of biopsies post-transplant has shown to lead to better graft function 3.5 years after transplantation1
- The purpose of this multi-site study is to describe the impact of targeted biopsies on altering pharmacological management in this pediatric patient group

Study Aims

- Identify demographics of pediatric renal transplant patients across Ireland from 2007-2017
- Identify treatment changes in post-transplant renal biopsy patients

Methods

- IRB approval was sought by Temple Street Children’s University Hospital
- A retrospective review of 103 patients who received a renal transplant from 2007-2017 was analyzed
- Patients who underwent at least one renal biopsy at Temple Street Children’s University Hospital and Our Lady Children’s Hospital, Crumlin, were included
- Data collected: demographic data, clinical indications, biopsy and histological findings
- Data analyzed via Microsoft Excel 2016

Results

- 26 of 103 patients (24%) who received a renal transplant had one or more biopsies (49 total)
- Mean age is 9.64 years ± 4.26 years
- No difference in age distribution of those biopsied and not biopsied (p = 0.2874 T test)
- Time between transplant and biopsy:
  - ≤ 1 year = 21/49 • 2-5 years = 17/49 • > 5 years = 11/49
- Changes in treatment after biopsy due to:
  - Acute rejection n = 20
  - Tacrolimus toxicity n = 5
  - Donor-specific antibodies n = 5
  - Two patients had changes in their antibiotics and there was no change in remaining patients (n=17)
  - No major complications were seen during biopsy
  - The following figures are representative of all 49 biopsies

Conclusions

- Blind treatment without a biopsy can be potentially harmful
- With the single clinical marker of a raised creatinine, 41% of biopsied patients required increased immunosuppression
- The evidence does not suggest protocol biopsies would be advantageous - particularly as complications may occur
- Judicious use of biopsies in the 24% of transplant patients with indications led to targeted treatment with few risks of over immunosuppression and complications

Next Steps

A long-term follow up study of outcomes comparing centers that use targeted versus protocol biopsies is recommended.

Citation


Acknowledgements

Dr. Elaine Kohler Summer Academy of Global Health Research and the Medical College of Wisconsin Office of Global Health